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Background: Saccharomyces cerevisiae is a yeast which has been used for decades mainly as 
probiotic in the medical field. For a long time, it was considered as safe and non-pathogenic but 
recently, the number of infections caused by this yeast has been rising particularly in 
immunocompromised patients. This study presents a review of cases of deep infection caused by S. 
cerevisiae during the last 10 years including the clinical relevance and therapeutic management.
Materials/methods: The systemic infections due to Saccharomyces cerevisiae that occurred at the 
University Hospital of Liege from January 2000 to January 2019 were reviewed by using the Glims 
laboratory database. The minimal inhibitory concentrations (MICs) obtained by microdilution with 
Sensititre YeastOne YO10 test (Trek, USA) was compared to the therapeutic management applied.
Results: During this period, from 2016 to 2019, 11 patients were diagnosed with fungemia due to S. 
cerevisiae. All the systemic infections occurred in patients presenting one or multiple risk factors: 4 out 
of 11 were oncologic patients upon chemotherapy, corticoids or radiotherapy, 3 were under Enterol® 
and 9 patients received broad-spectrum antibiotics prior to fungemia. Only 3 patients who were 
immunocompromised had multiple positive blood cultures (9, 5 and 3 respectively) contrary to the 
others, which had only one positive bottle. High MIC values were obtained for fluconazole (4-256 
µg/mL), while MICs for amphotericin B were low (0.002-2 µg/mL). Among the 11 patients, 4 were 
treated with fluconazole, 2 with Amphotericin B and 5 only by catheter removal. All had a favorable 
outcome, except 2 oncologic patients who were under fluconazole (MIC = 8 µg/mL) and one who 
wasn’t treated due to her critical state.
Conclusions: The last 3 years, we noticed the emergence of blood infections caused by this yeast. 
They progressed into invasive conditions only in immunocompromised patients, who had been directly 
in contact with Enterol® or indirectly by caregivers. Therefore, it is necessary to limit the contact of 
fragile patients with probiotics containing the yeast. About the treatment, Amphotericin B seems to be 
the best option but due to its toxicity, fluconazole is preferably used, the outcome depending on the 
case.
